An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts.
Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco.
The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HIV and acute respiratory distress syndrome (ARDS) associated with the virus that causes COVID-19.
Fired Winnipeg lab scientist listed as co-inventor on two Chinese government patents
windsorstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from windsorstar.com Daily Mail and Mail on Sunday newspapers.
As the autumn elections approached, Trudeau, O Toole and Singh argued with each other in the last House of Commons meeting
justicenewsflash.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from justicenewsflash.com Daily Mail and Mail on Sunday newspapers.
Free Press Head Start for June 18
winnipegfreepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegfreepress.com Daily Mail and Mail on Sunday newspapers.